TROV vs. FATE, ALEC, KYTX, EXOZ, CCCC, SNTI, CRDL, HLVX, CLLS, and ELUT
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Fate Therapeutics (FATE), Alector (ALEC), Kyverna Therapeutics (KYTX), Exozymes (EXOZ), C4 Therapeutics (CCCC), Senti Biosciences (SNTI), Cardiol Therapeutics (CRDL), HilleVax (HLVX), Cellectis (CLLS), and Elutia (ELUT). These companies are all part of the "medical" sector.
Cardiff Oncology vs.
Fate Therapeutics (NASDAQ:FATE) and Cardiff Oncology (NASDAQ:TROV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations.
In the previous week, Fate Therapeutics had 5 more articles in the media than Cardiff Oncology. MarketBeat recorded 5 mentions for Fate Therapeutics and 0 mentions for Cardiff Oncology. Fate Therapeutics' average media sentiment score of 0.47 beat Cardiff Oncology's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media.
Fate Therapeutics received 78 more outperform votes than Cardiff Oncology when rated by MarketBeat users. However, 73.09% of users gave Cardiff Oncology an outperform vote while only 67.51% of users gave Fate Therapeutics an outperform vote.
97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 10.0% of Cardiff Oncology shares are owned by institutional investors. 5.0% of Fate Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Fate Therapeutics has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
Cardiff Oncology has lower revenue, but higher earnings than Fate Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fate Therapeutics has a net margin of -1,325.43% compared to Cardiff Oncology's net margin of -3,688.31%. Fate Therapeutics' return on equity of -45.88% beat Cardiff Oncology's return on equity.
Fate Therapeutics currently has a consensus target price of $5.43, suggesting a potential upside of 389.06%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Fate Therapeutics is more favorable than Cardiff Oncology.
Summary
Fate Therapeutics beats Cardiff Oncology on 15 of the 18 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:TROV) was last updated on 4/20/2025 by MarketBeat.com Staff
